関連する実験動画
Updated: Jan 30, 2026

09:37
Dopamine Release at Individual Presynaptic Terminals Visualized with FFNs
Published on: August 31, 2009
25.3K
ドーパミンの放出をコレリン調節することで,努力的な行動が誘発されます
Gavin C Touponse1, Matthew B Pomrenze2, Teema Yassine1
1Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Nature
|January 28, 2026
まとめ
努力は報酬に対するドーパミン反応を増幅し,アセチルコリンが核アクンベンスのドーパミンアクソンに作用する. このメカニズムは,私たちが苦労して獲得した報酬を重視し,努力的な行動を動機付ける理由を説明します.
科学分野:
- 神経科学は神経科学である.
- 行動生物学 行動生物学
- 神経化学 神経化学とは
背景:
- 個人は,多くの場合,より多くの努力を必要とする報酬を好み,これは進化的フィットネスを高める現象です.
- この労力に基づく報酬評価のニューラル基盤は,ほとんど不明のままである.
研究 の 目的:
- 努力が報酬の処理に影響を及ぼし,行動を動機付ける神経メカニズムを調査する.
- 努力依存報酬増幅におけるドーパミンとアセチルコリンの役割を明らかにする.
主な方法:
- ネズミのモデルにおけるin vivo電気生理学と薬理学.
- 核アクンベンスのドーパミン放出量の測定.
- ドーパミンのアクソンにおけるコリナージックシグナル伝達の操作.
- 努力による選択を測定する行動分析.
主要な成果:
- 高度の労力の報酬は,核アクンベンスのアセチルコリン放出を誘発し,ドーパミンの放出を促進します.
- アセチルコリンは,ドーパミンアクソン末端のニコチン受容体に作用し,ドーパミンの放出を増大します.
- コリナージック調節の薬理学的阻害は,低労力の報酬消費に影響を与えることなく,精力的な行動を選択的に損なう.
結論:
- 努力は,ドーパミンのアクソンの局所的なアセチルコリン調節を通じて,報酬へのドーパミンのシグナル伝達を強化します.
- このメカニズムは,努力的な行動の価値に対する神経生物学的な基礎を提供します.
- この発見は,報酬経路におけるアセチルコリン-ドーパミン相互作用に関する in vitro および in vivo 観測を一致させるものである.
関連する概念動画
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
902
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
902
Energy to Drive Translocation
2.8K
Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
Generally, polypeptides are unfolded by two distinct...
2.8K
Cholinergic Antagonists: Therapeutic Uses
1.4K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.4K
Cholinergic Neurons: Neurotransmission
5.4K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
5.4K
Cholinergic Receptors: Muscarinic
5.1K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine.
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.1K
Cholinergic Receptors: Nicotinic
5.6K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
5.6K

